| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Emmaus Life Sciences Inc (OTCQB: EMMAW)
EMMAW Technical Analysis
5
| As on 14th Mar 2022 EMMAW STOCK Price closed @ 0.03 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.05 & Strong Sell for SHORT-TERM with Stoploss of 0.06 we also expect STOCK to react on Following IMPORTANT LEVELS. |
EMMAWSTOCK Price
| Open | 0.03 | Change | Price | % |
| High | 0.03 | 1 Day | 0.00 | 0.00 |
| Low | 0.03 | 1 Week | -0.02 | -40.00 |
| Close | 0.03 | 1 Month | -0.03 | -50.00 |
| Volume | 10006 | 1 Year | 0.01 | 50.00 |
| 52 Week High 0.28 | 52 Week Low 0.00 | ||||
OTCQB USA Most Active Stocks
| SPYR | 0.00 | % |
| EMED | 0.00 | % |
| SOWG | 0.46 | % |
| BLEG | 0.00 | % |
| WDLF | 0.00 | % |
| BMIX | 0.01 | % |
| FNMA | 6.10 | % |
| BEGI | 0.00 | % |
| GRSLF | 0.23 | % |
| VPLM | 0.01 | % |
OTCQB USA Top Gainers Stocks
OTCQB USA Top Losers Stocks
| EMMAW Daily Charts |
EMMAW Intraday Charts |
Whats New @ Bazaartrend |
EMMAW Free Analysis |
|
|
EMMAW Important Levels Intraday
| RESISTANCE | 0.03 |
| RESISTANCE | 0.03 |
| RESISTANCE | 0.03 |
| RESISTANCE | 0.03 |
| RESISTANCE | 0.03 |
| RESISTANCE | 0.03 |
| RESISTANCE | 0.03 |
| RESISTANCE | 0.03 |
EMMAW Forecast March 2026
| 4th UP Forecast | 1.07 |
| 3rd UP Forecast | 0.74 |
| 2nd UP Forecast | 0.53 |
| 1st UP Forecast | 0.32 |
| 1st DOWN Forecast | -0.26 |
| 2nd DOWN Forecast | -0.47 |
| 3rd DOWN Forecast | -0.68 |
| 4th DOWN Forecast | -1.01 |
EMMAW Weekly Forecast
| 4th UP Forecast | 0.07 |
| 3rd UP Forecast | 0.06 |
| 2nd UP Forecast | 0.05 |
| 1st UP Forecast | 0.04 |
| 1st DOWN Forecast | 0.02 |
| 2nd DOWN Forecast | 0.01 |
| 3rd DOWN Forecast | 0.00 |
| 4th DOWN Forecast | -0.01 |
EMMAW Forecast2026
| 4th UP Forecast | 1.09 |
| 3rd UP Forecast | 0.75 |
| 2nd UP Forecast | 0.54 |
| 1st UP Forecast | 0.33 |
| 1st DOWN Forecast | -0.27 |
| 2nd DOWN Forecast | -0.48 |
| 3rd DOWN Forecast | -0.69 |
| 4th DOWN Forecast | -1.03 |
Emmaus Life Sciences Inc ( OTCQB USA Symbol : EMMAW )
Sector : Other And Other Stocks in Same Sector
Sector : Other And Other Stocks in Same Sector
EMMAW Business Profile
Emmaus Life Sciences, Inc. engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older; NutreStore L-glutamine powder; and AminoPure, a nutritional supplement. The company also develops therapeutic products based on cell sheet technology for the treatment of corneal diseases. In addition, it focuses on developing pharmaceutical-grade L-glutamine oral powder for diverticulosis. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California. Address:
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service